Examining the clinical and genetic spectrum of maturity-onset diabetes of the young (MODY) in Iran

Sara Asgarian,Hossein Lanjanian,Shiva Rahimipour Anaraki,Farzad Hadaegh,Maryam Moazzam-Jazi,Leila Najd-Hassan-Bonab,Sajedeh Masjoudi,Asiyeh Sadat Zahedi,Maryam Zarkesh,Bita Shalbafan,Mahdi Akbarzadeh,Sahand Tehrani Fateh,Davood Khalili,Amirabbas Momenan,Narges Sarbazi,Mehdi Hedayati,Fereidoun Azizi,Maryam S Daneshpour
DOI: https://doi.org/10.1038/s41598-024-70864-y
2024-08-27
Abstract:Maturity-onset diabetes of the young (MODY) is an uncommon monogenic type of diabetes mellitus. Detecting genetic variants for MODY is a necessity for precise diagnosis and treatment. The majority of MODY genetic predisposition has been documented in European populations and a lack of information is present in Iranians which leads to misdiagnosis as a consequence of defects in unknown variants. In this study, using genetic variant information of 20,002 participants from the family-based TCGS (Tehran Cardiometabolic Genetic Study) cohort, we evaluated the genetic spectrum of MODY in Iran. We concentrated on previously discovered MODY-causing genes. Genetic variants were evaluated for their pathogenicity. We discovered 6 variants that were previously reported in the ClinVar as pathogenic/likely pathogenic (P/LP) for MODY in 45 participants from 24 families (INS in 21 cases, GCK in 13, HNF1B in 8, HNF4A, HNF1A, and CEL in 1 case). One potential MODY variant with Uncertain Risk Allele in ClinVar classification was also identified, which showed complete disease penetrance (100%) in four subjects from one family. This is the first family-based study to define the genetic spectrum and estimate the prevalence of MODY in Iran. The discovered variants need to be investigated by additional studies.
What problem does this paper attempt to address?